Financials in USD. Standardized financial statements.
A compact view of how INmune Bio, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $50,000 | $14,000 | $155,000 | $374,000 | $181,000 | $11,000 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +257.1% | -91.0% | -58.6% | +106.6% | +1545.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $50,000 | $14,000 | $155,000 | $374,000 | $181,000 | $11,000 | $0 | $0 | $0 | $0 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $30.92M | $42.65M | $29.90M | $26.32M | $29.33M | $12.24M | $7.76M | $12.44M | $981,480 | $227,491 |
| Operating Income? | -$30.87M | -$42.63M | -$29.74M | -$25.95M | -$29.15M | -$12.23M | -$7.76M | -$12.44M | -$981,000 | -$227,000 |
| EBITDA? | -$30.79M | -$42.08M | $0 | $0 | $0 | $0 | -$7.68M | $0 | $149,990 | -$50,000 |
| Income Before Tax | -$45.93M | -$42.08M | -$30.01M | -$27.30M | -$30.34M | -$12.10M | -$7.68M | -$12.44M | -$831,000 | -$277,000 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$45.93M | -$42.08M | -$30.01M | -$27.30M | -$30.34M | -$12.10M | -$7.68M | -$12.44M | -$831,000 | -$277,000 |
| EPS? | $-1.86 | $-2.11 | $-1.67 | $-1.52 | $-1.88 | $-1.01 | $-0.89 | $-1.11 | $-0.07 | $-0.05 |
| Diluted EPS? | $-1.86 | $-2.11 | $-1.67 | $-1.52 | $-1.88 | $-1.01 | $-0.89 | $-1.11 | $-0.07 | $-0.05 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality